This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Eclache, V. Articles by Fenaux, P. Search for Related Content PubMed PubMed Citation Articles by Eclache, V. Articles by Fenaux, P.

Unusual clonal evolution involving 5q in a case of myelodysplastic syndrome with deletion 5q 31 treated with lenalidomide

Services d’Hematologie Clinique et Biologique, Hôpital Avicenne, Université Paris-XIII, APHP, Bobigny, France

Correspondence: Virginie Eclache, Services d’hematologie clinique & biologique, Hôpital Avicenne, Universite Paris-XIII, APHP, 125, rue de Stalingrad, 93000 Bobigny, France E-mail: virginie.eclache{at}avc.ap-hop-paris.fr

Lenalidomide is a very active drug in myelodysplastic syndrome with del (5q). We report such a patient treated with this drug who developed unusual complex cytogenetic abnormalities, which were elucidated by multi-FISH and FISH analysis as jumping translocations involving the long arm of chromosome 5, that resulted in an increase of 5q copies. This unusual findings is discussed in the context of resistance to lenalidomide observed in this patient.

Key words: lenalidomide, myelodysplastic syndromes, del(5q) MDS, transfusion-dependent, case study.

This article has been cited by other articles:

				M. Jadersten, L. Saft, A. Pellagatti, G. Gohring, J. S. Wainscoat, J. Boultwood, A. Porwit, B. Schlegelberger, and E. Hellstrom-Lindberg Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression Haematologica, December 1, 2009; 94(12): 1762 - 1766. [Abstract] [Full Text] [PDF]